Regeneron Pharmaceuticals (REGN) Equity Ratio (2009 - 2026)

Regeneron Pharmaceuticals' Equity Ratio history runs 18 years deep, the most recent figure standing at 0.77 for Q1 2026.

• In Q1 2026, Equity Ratio fell 1.77% year-over-year to 0.77; the TTM figure through Mar 2026 stood at 0.77 (down 1.77% YoY), while the FY2025 annual figure was 0.77, down 0.87% from the prior year.
• Equity Ratio was 0.77 for Q1 2026 at Regeneron Pharmaceuticals, roughly flat from 0.77 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.79 in Q1 2024 to a low of 0.76 in Q1 2022.
• Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.78 in 2024.
• The sharpest annual moves came in 2022 and 2026: Equity Ratio rose 12.15% in 2022, then dropped 1.77% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.78 in 2022, then increased by 1.21% to 0.79 in 2023, then fell by 0.99% to 0.78 in 2024, then fell by 0.87% to 0.77 in 2025, then decreased by 0.23% to 0.77 in 2026.
• The last three Equity Ratio figures came in at 0.77 (Q1 2026), 0.77 (Q4 2025), and 0.77 (Q3 2025), per Business Quant data.